June 2019 - Volume 3 - Issue - Contributor Index

Author:
H, R. A
Author:
Ha, C. Y.
Author:
Haaber, J.
Author:
Haas, R.

ISOLATED PRIMARY ADRENAL LYMPHOMA (IPAL) - AN EMERGING LYMPHOMA ENTITY? RESULTS OF A RETROSPECTIVE MULTICENTER STUDY: PF311

Majidi, F.; Martino, S.; Kondakci, M.; More

HemaSphere. 3:108, June 2019.

Author:
Haas, S.
Author:
Haas, V.

RANDOMIZED PHASE III HOVON-100 STUDY OF CLOFARABINE COMBINED WITH STANDARD TREATMENT IN ADULT PATIENTS WITH NEWLY DIAGNOSED ALL: PS937

Rijneveld, A.; van der Holt, B.; de Weerdt, O.; More

HemaSphere. 3:421-422, June 2019.

Author:
Haase, D.
Author:
Haase, M.

ISOLATED PRIMARY ADRENAL LYMPHOMA (IPAL) - AN EMERGING LYMPHOMA ENTITY? RESULTS OF A RETROSPECTIVE MULTICENTER STUDY: PF311

Majidi, F.; Martino, S.; Kondakci, M.; More

HemaSphere. 3:108, June 2019.

Author:
Habermann, T.
Author:
Habets, R.
Author:
Haboubi, T.
Author:
Habra, M. A.

ISOLATED PRIMARY ADRENAL LYMPHOMA (IPAL) - AN EMERGING LYMPHOMA ENTITY? RESULTS OF A RETROSPECTIVE MULTICENTER STUDY: PF311

Majidi, F.; Martino, S.; Kondakci, M.; More

HemaSphere. 3:108, June 2019.

Author:
hachicha, M.

NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: LONG TERM RESULTS OF MULTI-CENTER EXPERIENCE IN TURKEY: PS1245

Ferhanoglu, B.; Ozbalak, M.; Bekoz, H.; More

HemaSphere. 3:567-568, June 2019.

Author:
Hadar, E.
Author:
Haddadeen, M.
Author:
Hadjiev, E.
Author:
Haertle, L.

HACE1, A NOVEL TUMOR SUPPRESSOR GENE WHICH REGULATE THE RESPONSE OF VENETOCLAX, GANT61 AND NECROPTOSIS ACTIVATORS BY CONTROLLING C-FLIP, GLI2 AND BCL2 GENES IN ACUTE MYELOID LEUKEMIA: PS1001

Garitano, A.; Teufel, E.; Kreckel, J.; More

HemaSphere. 3:450, June 2019.

Author:
Haferlach, C.

INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: PF532

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3:218-219, June 2019.

GENOMIC ARRAYS IDENTIFY HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA WITH GENOMIC COMPLEXITY: A MULTI-CENTER STUDY: PS1133

Leeksma, A.; Baliakas, P.; Moysiadis, T.; More

HemaSphere. 3:513, June 2019.

Author:
Haferlach, T.

INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: PF532

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3:218-219, June 2019.

MARS: MUTATION-ADJUSTED RISK SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS: S1611

Jawhar, M.; Schwaab, J.; Álvarez-Twose, I.; More

HemaSphere. 3:742-743, June 2019.

Author:
Hagberg, O.
Author:
Hagedoorn, R.
Author:
Hageman, L.
Author:
Hagemeister, F.

RITUXIMAB-BEAM AND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR PATIENTS (PTS) WITH RELAPSED FOLLICULAR LYMPHOMA (FL) NOT ABLE TO RECEIVE AN ALLOGENEIC SCT: 8-YEAR MEDIAN FOLLOW-UP RESULTS: PS1561

Khouri, I.; Milton, D.; Young, K.; More

HemaSphere. 3:720, June 2019.

Author:
Hagiwara, S.
Author:
Haider, R. Z.H.
Author:
Haidouri, S.
Author:
Haioun, C.

REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM: S1600

Thieblemont, C.; Legouill, S.; Di Blasi, R.; More

HemaSphere. 3:736-737, June 2019.

Author:
Hajduk, A.

CONSTRUCTION OF A PROGNOSTIC MODEL FOR HLH IN ADULTS - ANALYSIS FROM THE PALG HLH IN ADULTS DATABASE: PF350

Machowicz, R.; Staniak, M.; Waszczuk-Gajda, A.; More

HemaSphere. 3:126-127, June 2019.

Author:
Hajek, R.

EVOLVING TREATMENT PATTERNS IN MULTIPLE MYELOMA (MM) DIFFER BY AGE AND REGION: ANALYSIS FROM INSIGHT MM, A GLOBAL, PROSPECTIVE, OBSERVATIONAL STUDY: PF601

Chari, A.; Weisel, K. C.; Usmani, S. Z.; More

HemaSphere. 3:254, June 2019.

OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS: PF602

Montefusco, V.; Gay, F.; Spada, S.; More

HemaSphere. 3:254-255, June 2019.

ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR: PF608

Pour, L.; Efebera, Y. A.; Granell, M.; More

HemaSphere. 3:257-258, June 2019.

UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA: PS1349

Mateos, M.-V.; Kumar, S.; Gonzalez, V.; More

HemaSphere. 3:616, June 2019.

COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US: PS1419

Davies, F.; Rifkin, R.; Costello, C.; More

HemaSphere. 3:652-653, June 2019.

QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA-THAL-DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION: PS1509

Ludwig, H.; Pönisch, W.; Knop, S.; More

HemaSphere. 3:695-696, June 2019.

Author:
Hájek, R.
Author:
Hakimeh, D.
Author:
Hakmi, A.
Author:
Halahleh, K.
Author:
Halder, R.
Author:
Halka, J.

OPEN-LABEL STUDY OF GILTERITINIB, GILTERITINIB PLUS AZACITIDINE, OR AZACITIDINE ALONE IN NEWLY DIAGNOSED FLT3-MUTATED AML PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY: RESULTS FROM THE SAFETY COHORT: PS1065

Esteve, J.; Schots, R.; Del Castillo, Bernal T.; More

HemaSphere. 3:482, June 2019.

Author:
Halkes, C.
Author:
Halkes, S.

RANDOMIZED PHASE III HOVON-100 STUDY OF CLOFARABINE COMBINED WITH STANDARD TREATMENT IN ADULT PATIENTS WITH NEWLY DIAGNOSED ALL: PS937

Rijneveld, A.; van der Holt, B.; de Weerdt, O.; More

HemaSphere. 3:421-422, June 2019.

Author:
Hall, C.

SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY: PF691

Todd, S.; Infirri, Sardo S.; Miah, H.; More

HemaSphere. 3:299-300, June 2019.

TRANSFUSION DEPENDENCY IS ASSOCIATED WITH PRESENCE OF TOXIC IRON SPECIES AND INFERIOR SURVIVAL IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES: S838

Hoeks, M.; Bagguley, T.; Roelofs, R.; More

HemaSphere. 3:373, June 2019.

Author:
Hall, R.
Author:
Hallal, M.
Author:
Hallam, S.
Author:
Hallek, M.

GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY: S105

Tausch, E.; Bahlo, J.; Robrecht, S.; More

HemaSphere. 3:4, June 2019.

HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL: S106

Al-Sawaf, O.; Lilienweiss, E.; Bahlo, J.; More

HemaSphere. 3:4-5, June 2019.

FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION-FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES: S149

Fischer, K.; Al-Sawaf, O.; Bahlo, J.; More

HemaSphere. 3:26-27, June 2019.

Author:
Halpern, A. B.

SAFETY AND RESOURCE UTILIZATION FOLLOWING EARLY HOSPITAL DISCHARGE AFTER INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA (AML): A 4-YEAR RETROSPECTIVE ANALYSIS: PF253

Howard, N. P.; Halpern, A. B.; Othus, M.; More

HemaSphere. 3:78, June 2019.

Author:
Haltner, A.

OUTCOMES OF PATIENTS WITH T(11;14) MULTIPLE MYELOMA: AN INTERNATIONAL MYELOMA WORKING GROUP MULTICENTER STUDY: PF564

Kumar, S.; Goldschmidt, H.; Mateos, M.-V.; More

HemaSphere. 3:234-235, June 2019.

Author:
Halton, E.

A PHASE I FIRST-IN-HUMAN CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION: S1634

Palomba, M. L.; Batlevi, C.; Riviere, I.; More

HemaSphere. 3:755, June 2019.

Author:
Halvorsen, B.
Author:
Hamada, S.
Author:
Hamada, T.
Author:
Hamadani, M.
Author:
Hamaguchi, I.
Author:
Hamard, S.
Author:
Hamdani, M.
Author:
Hamdy, A.
Author:
Hamdy, M.
Author:
Hamed, G.
Show: